MX2022004101A - Composiciones de oligonucleotidos y metodos de uso de las mismas. - Google Patents
Composiciones de oligonucleotidos y metodos de uso de las mismas.Info
- Publication number
- MX2022004101A MX2022004101A MX2022004101A MX2022004101A MX2022004101A MX 2022004101 A MX2022004101 A MX 2022004101A MX 2022004101 A MX2022004101 A MX 2022004101A MX 2022004101 A MX2022004101 A MX 2022004101A MX 2022004101 A MX2022004101 A MX 2022004101A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- oligonucleotide compositions
- compositions
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Abstract
Entre otras cosas, la presente divulgación proporciona oligonucleótidos y composiciones de los mismos. En algunas realizaciones, los oligonucleótidos y las composiciones que se proporcionan son útiles para la modificación de la adenosina. En algunas realizaciones, la presente divulgación proporciona métodos para tratar diversas afecciones, trastornos o enfermedades que pueden beneficiarse de la modificación de la adenosina.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962911334P | 2019-10-06 | 2019-10-06 | |
US202062959917P | 2020-01-11 | 2020-01-11 | |
US202063022559P | 2020-05-10 | 2020-05-10 | |
US202063069696P | 2020-08-24 | 2020-08-24 | |
PCT/US2020/054436 WO2021071858A1 (en) | 2019-10-06 | 2020-10-06 | Oligonucleotide compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004101A true MX2022004101A (es) | 2022-04-26 |
Family
ID=75437497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004101A MX2022004101A (es) | 2019-10-06 | 2020-10-06 | Composiciones de oligonucleotidos y metodos de uso de las mismas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230220384A1 (es) |
EP (1) | EP4022059A4 (es) |
JP (1) | JP2022551124A (es) |
KR (1) | KR20220076508A (es) |
CN (1) | CN114585737A (es) |
AU (1) | AU2020363391A1 (es) |
BR (1) | BR112022006205A2 (es) |
CA (1) | CA3154768A1 (es) |
IL (1) | IL291933A (es) |
MX (1) | MX2022004101A (es) |
WO (1) | WO2021071858A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
AU2017234150B2 (en) | 2016-03-13 | 2021-09-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
CN110088113A (zh) | 2016-11-23 | 2019-08-02 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
EP3642182A4 (en) | 2017-06-21 | 2020-12-09 | Wave Life Sciences Ltd. | COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS |
AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
JP2020537518A (ja) | 2017-10-12 | 2020-12-24 | ウェーブ ライフ サイエンシーズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
KR20210149750A (ko) * | 2019-03-20 | 2021-12-09 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 제조에 유용한 기술 |
US20230194709A9 (en) * | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
EP4363574A1 (en) * | 2021-06-29 | 2024-05-08 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2023220440A1 (en) * | 2022-05-12 | 2023-11-16 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
WO2023220428A1 (en) * | 2022-05-12 | 2023-11-16 | Wave Life Sciences Ltd. | Compositions for editing ass1 transcripts and methods thereof |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024017817A1 (en) * | 2022-07-18 | 2024-01-25 | F. Hoffmann-La Roche Ag | Editing oligonucleotide |
GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014169206A2 (en) * | 2013-04-11 | 2014-10-16 | Carnegie Mellon University | Divalent nucleobase compounds and uses therefor |
KR102423317B1 (ko) * | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
US10941402B2 (en) * | 2016-09-01 | 2021-03-09 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded RNA-editing oligonucleotides |
EP3642182A4 (en) * | 2017-06-21 | 2020-12-09 | Wave Life Sciences Ltd. | COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS |
-
2020
- 2020-10-06 CA CA3154768A patent/CA3154768A1/en active Pending
- 2020-10-06 JP JP2022520901A patent/JP2022551124A/ja active Pending
- 2020-10-06 AU AU2020363391A patent/AU2020363391A1/en active Pending
- 2020-10-06 BR BR112022006205A patent/BR112022006205A2/pt unknown
- 2020-10-06 US US17/766,677 patent/US20230220384A1/en active Pending
- 2020-10-06 MX MX2022004101A patent/MX2022004101A/es unknown
- 2020-10-06 CN CN202080069504.2A patent/CN114585737A/zh active Pending
- 2020-10-06 EP EP20873624.9A patent/EP4022059A4/en active Pending
- 2020-10-06 WO PCT/US2020/054436 patent/WO2021071858A1/en active Application Filing
- 2020-10-06 KR KR1020227015085A patent/KR20220076508A/ko unknown
-
2022
- 2022-04-04 IL IL291933A patent/IL291933A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20230220384A1 (en) | 2023-07-13 |
EP4022059A1 (en) | 2022-07-06 |
WO2021071858A1 (en) | 2021-04-15 |
CA3154768A1 (en) | 2021-04-15 |
BR112022006205A2 (pt) | 2022-07-19 |
IL291933A (en) | 2022-06-01 |
CN114585737A (zh) | 2022-06-03 |
KR20220076508A (ko) | 2022-06-08 |
JP2022551124A (ja) | 2022-12-07 |
EP4022059A4 (en) | 2023-11-01 |
AU2020363391A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
MX2023005326A (es) | Composiciones de oligonucleótidos y métodos de las mismas. | |
MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
WO2020227691A3 (en) | Oligonucleotide compositions and methods of use thereof | |
MX2021009178A (es) | Composiciones de oligonucleotidos y metodos de las mismas. | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
NZ754731A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
MX2022002877A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. | |
EP4219713A3 (en) | Products and compositions | |
MX2021012862A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
WO2016106400A3 (en) | Rna interference agents for gst-pi gene modulation | |
EP3995581A3 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
MX2022013356A (es) | Avv que codifica mirna dirigido al gen htt y usos del mismo. | |
WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2023001450A (es) | Composiciones y metodos para la inhibicion de la expresion de plp1. | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
MX2015015564A (es) | Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos. | |
MX2021013602A (es) | Inhibidores de jak. | |
MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
WO2017007886A3 (en) | Compositions for inhibiting dux4 gene expression and uses thereof | |
MX2018012545A (es) | Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. |